abrdn Income Credit Strategies ACP Pharma — Accounts Receivable Net
Other segment segments
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNet.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — accounts receivable net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — accounts receivable net?
- abrdn Income Credit Strategies (ACP) reported pharma — accounts receivable net of $27M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — accounts receivable net changed year-over-year?
- abrdn Income Credit Strategies's pharma — accounts receivable net decreased by 30.8% year-over-year, from $39M to $27M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — accounts receivable net?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — accounts receivable net has grown at a 11.2% compound annual growth rate (CAGR), from $95M to $145M.
- What does pharma — accounts receivable net mean?
- Measures the amount of money owed to the Pharma segment by customers for goods or services delivered, net of any allowances for doubtful accounts. This metric provides insight into the segment's credit management and the efficiency of its revenue collection cycle. High levels relative to sales may indicate potential collection risks or changes in customer payment terms.